Beyond Air Inc XAIR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XAIR is a good fit for your portfolio.
News
-
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
-
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
-
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
Trading Information
- Previous Close Price
- $1.22
- Day Range
- $1.20–1.32
- 52-Week Range
- $1.06–6.36
- Bid/Ask
- $1.30 / $1.30
- Market Cap
- $59.67 Mil
- Volume/Avg
- 327,247 / 306,487
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 59.36
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 98
- Website
- https://www.beyondair.net
Comparables
Valuation
Metric
|
XAIR
|
ICVX
|
ANIK
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.22 | 3.30 | 1.91 |
Price/Sales | 59.36 | — | 2.43 |
Price/Cash Flow | — | — | 39.13 |
Price/Earnings
XAIR
ICVX
ANIK
Financial Strength
Metric
|
XAIR
|
ICVX
|
ANIK
|
---|---|---|---|
Quick Ratio | 2.73 | 17.59 | 3.50 |
Current Ratio | 3.39 | 18.06 | 5.26 |
Interest Coverage | −36.73 | — | — |
Quick Ratio
XAIR
ICVX
ANIK
Profitability
Metric
|
XAIR
|
ICVX
|
ANIK
|
---|---|---|---|
Return on Assets (Normalized) | −60.39% | −29.30% | −1.35% |
Return on Equity (Normalized) | −115.09% | −31.87% | −1.65% |
Return on Invested Capital (Normalized) | −79.62% | −34.69% | −2.24% |
Return on Assets
XAIR
ICVX
ANIK
Medical Devices Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ABT
| Abbott Laboratories | Gmftrxkz | Nwpscjw | $184.2 Bil | |
SYK
| Stryker Corp | Hzkfcplgfz | Tnkq | $125.1 Bil | |
MDT
| Medtronic PLC | Hyznqkyl | Yjxqr | $108.5 Bil | |
BSX
| Boston Scientific Corp | Ckrfdmc | Jyjgtt | $107.1 Bil | |
EW
| Edwards Lifesciences Corp | Kbcnthxr | Bqhdhd | $51.4 Bil | |
DXCM
| DexCom Inc | Cvvjnxcmj | Txqk | $50.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Kplcvgvrq | Gfm | $25.0 Bil | |
PHG
| Koninklijke Philips NV ADR | Znstygxk | Thjqzdh | $24.4 Bil | |
ALGN
| Align Technology Inc | Rbghmlms | Sxgslf | $21.7 Bil | |
PODD
| Insulet Corp | Xbnbpwgsb | Qfslsj | $12.2 Bil |